Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.50 |
| ▸ | TARS1 | P26639 | 2/20 | 0.50 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28894185 | 0.89 | ADORA3 (0.54) | CYP2C19 | |
| SCHEMBL28894183 | 0.89 | ADORA3 (0.54) | CYP2C19 | |
| SCHEMBL5155877 | 0.86 | TARS1 (0.62) | P2RY12TARS1 | |
| SCHEMBL29389281 | 0.83 | ADORA3 (0.51) | CYP2C19 | |
| SCHEMBL1274809 | 0.83 | ADORA3 (0.51) | CYP2C19 | |
| SCHEMBL1274810 | 0.83 | ADORA3 (0.51) | CYP2C19 | |
| SCHEMBL1707366 | 0.83 | ADORA3 (0.51) | CYP2C19 | |
| SCHEMBL28671612 | 0.81 | ADORA3 (0.52) | CYP2C19 | |
| SCHEMBL28671616 | 0.81 | ADORA3 (0.52) | CYP2C19 | |
| SCHEMBL31490447 | 0.80 | KDM4E (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2815 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| US-12503720-B2 | Multiplexed profiling of RNA and DNA modifications | Alida Biosciences Inc. (US) | 2025-12-23 | — | — | US | claimed |
| US-20250345406-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-12338485-B2 | Multiplexed profiling of RNA and DNA modifications | Alida Biosciences Inc. (US) | 2025-06-24 | — | — | US | claimed |
| WO-2025122721-A1 | CHIMERIC PROTEINS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-12281360-B2 | RNA and DNA analysis using engineered surfaces | ALIDA BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | claimed |
| WO-2025049610-A1 | MULTI-ACTION PEPTIDES | SHATTUCK LABS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| EP-2755693-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2710136-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | Moderna Therapeutics, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| EP-2691101-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | Moderna Therapeutics, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151671-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151736-A2 | IN VIVO PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013039861-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2012158736-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | modeRNA Therapeutics (US) | 2012-11-22 | — | — | WO | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |
| US-20120251618-A1 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | US | claimed |